注射后24小时单次SPECT显像评估PSMA放射性药物治疗反应
本回顾性研究纳入50例接受177Lu-PSMA-617放射性药物治疗的患者共335个指标病灶,在每周期注射后24小时行SPECT/CT剂量学分析。结果显示病灶水平定量反应与患者水平PSA反应相关,而基线吸收剂量与病灶反应关系有限。
要点
- 46%的患者在第2周期后达到PSA50反应。
- PSA应答者的SPECT病灶反应高于无应答者,三种指标均达统计学显著。
- 基线吸收剂量与病灶反应关系有限,大部分反应方差无法仅由基线吸收剂量解释。
核心结论
- 在这项回顾性研究中,病灶水平的定量反应与患者水平的PSA反应相关。
- 基线吸收剂量与病灶水平反应之间仅观察到有限的关系,大部分反应方差仍无法仅由基线吸收剂量解释。
- 在放射性药物治疗中采用24小时单时间点建立剂量-反应关系存在一些局限性。
研究设计与样本
- 回顾性研究,纳入50例接受177Lu-PSMA-617放射性药物治疗的患者,共335个指标病灶。
- 在第1和第2周期注射后24小时行SPECT/CT剂量学分析,测量病灶吸收剂量,第2周期后计算病灶反应和PSA50反应。
主要发现
- 50例患者中46%在第2周期后达到PSA50反应。
- 335个指标病灶中58%为骨病灶、32%为淋巴结、10%为软组织转移灶。
- PSA应答者的SPECTmean反应为46.8%±26.1% vs 无应答者26.2%±24.5%(P=0.007)。
- PSA应答者的SPECTmaximum反应为45%±25.1% vs 无应答者19%±27.0%(P=0.001)。
- PSA应答者的SPECTVIP-PSMA反应为49.2%±30.3% vs 无应答者14%±34.7%(P=0.0005)。
关键数值与推荐
- PSA50反应定义为第2周期后PSA较基线下降50%。
- PSA反应与SPECTVIP-PSMA反应之间存在关联(R²=0.40,P<0.0001)。
- 24小时单时间点基线平均吸收剂量与SPECT病灶反应关系有限(R²=0.05,P=0.001)。
- 24小时单时间点基线最大吸收剂量与SPECT病灶反应关系有限(R²=0.03,P=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,在放射性药物治疗中采用24小时单时间点建立剂量-反应关系存在一些局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding the relationship between lesion-absorbed dose and tumor response in 177Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated 50 patients with 335 index lesions undergoing 177Lu-PSMA-617 RPT, who had dosimetry analysis performed on SPECT/CT at 24 h after cycles 1 and 2. First, we identified the index lesions for each patient and measured the lesion-based absorbed doses. Lesion-based response was calculated after cycle 2. Additionally, PSA50 response (a decline of 50% from baseline PSA) after cycle 2 was also calculated. The respective responses for mean and maximum absorbed doses and prostate-specific membrane antigen (PSMA) volumetric intensity product (VIP-PSMA) at cycles 1 and 2 were termed SPECTmean, SPECTmaximum, and SPECTVIP-PSMA, respectively. Results: Of the 50 patients reviewed, 46% achieved a PSA50 response after cycle 2. Of the 335 index lesions, 58% were osseous, 32% were lymph nodes, and 10% were soft-tissue metastatic lesions. The SPECT lesion-based responses were higher in PSA responders than in nonresponders (SPECTmean response of 46.8% ± 26.1% vs. 26.2% ± 24.5%, P = 0.007; SPECTmaximum response of 45% ± 25.1% vs. 19% ± 27.0%, P = 0.001; SPECTVIP-PSMA response of 49.2% ± 30.3% vs. 14% ± 34.7%, P = 0.0005). An association was observed between PSA response and SPECTVIP-PSMA response (R 2 = 0.40 and P < 0.0001). A limited relationship was found between baseline absorbed dose measured with a 24-h single time point and SPECT lesion-based response (R 2 = 0.05, P = 0.001, and R 2 = 0.03, P = 0.007, for mean and maximum absorbed doses, respectively). Conclusion: In this retrospective study, quantitative lesion-based response correlated with patient-level PSA response. We observed a limited relationship between baseline absorbed dose and lesion-based responses. Most of the variance in response remains unexplained solely by baseline absorbed dose. Establishment of a dose-response relationship in RPT with a single time point at 24 h presented some limitations.
引用
- Yadav S, Jiang F, Kurkowska S, et al. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. J Nucl Med. 2024. PMID: 38724282. doi:10.2967/jnumed.123.267208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。